Zydus Lifesciences Ltd on Wednesday said it has signed an exclusive development, licensing, supply and commercialisation pact with Synthon BV of the Netherlands for a novel oncology product for an ...

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...

Zydus Lifesciences has partnered with Synthon BV in a deal to develop, license, supply, and commercialize a novel oncology drug in the US. The agreement aims to target a $1.5 billion market, with ...

Zydus, a leading, discovery-based, global pharmaceutical company announced that the US FDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of ...

Zydus Lifesciences’ (Zydus) Q3FY25 revenue was in line with our expectations, but lower sales of gRevlimid and gAsacol led to a miss in earnings. Higher sales of Mirabegron and new launches led ...

Zydus Lifesciences Ltd received the “No Observation” from US Food and Drug Administration in its recently concluded surveillance inspection of its API (Active Pharmaceutical Ingredients) manuf ...

Zydus Wellness is engaged in the development, production, marketing and distribution of health and wellness products. It has 7 leading brands in its portfolio, namely Complan, Sugar Free ...

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Under the terms of the agreement, Beihai Biotech will be responsible for the manufacturing and supply of the product while Zydus will be responsible for commercialisation of the product in the US, it ...